Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Santarus, Inc.
Positive PK Data from Investigator-Initiated Pilot Study with ZEGERID to Be Presented in Poster Session at DDW
June 15th, 2009
Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, announced that positive pharmacokinetic (PK) data from an investigator-initiated pilot study will be available in a poster session presentation at the Digestive Disease Week (DDW) 2009 Annual Meeting in Chicago. The pilot study, supported by a grant from Santarus, assessed PK differences between immediate-release ZEGERID® Powder for Oral Suspension (omeprazole/sodium bicarbonate) 40 mg and delayed-release omeprazole capsules 40 mg in patients with gastroesophageal reflux disease (GERD) associated with gastroparesis (delayed gastric emptying). The seven-day randomized, open-label, crossover study...
Source: Biotech Business Week (2009-06-15)
|
